The lack of long-term followup is one large problem; thanks for the post. A related problem is that effectiveness in the real world is normally less than in the trial, for many reasons. For both of these, CMS could require pharma and device makers to carry out long-term observational studies, and should. No one else can, I think.
The lack of long-term followup is one large problem; thanks for the post. A related problem is that effectiveness in the real world is normally less than in the trial, for many reasons. For both of these, CMS could require pharma and device makers to carry out long-term observational studies, and should. No one else can, I think.
The lack of long-term followup is one large problem; thanks for the post. A related problem is that effectiveness in the real world is normally less than in the trial, for many reasons. For both of these, CMS could require pharma and device makers to carry out long-term observational studies, and should. No one else can, I think.
Bernie Black, Northwestern University